Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03434379 · ClinicalTrials.gov registry record · Phase 3
A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
A Phase 3 study of Carcinoma, Hepatocellular, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 558
- Enrollment target
- 20
- Study locations
NCT03434379 is a Phase 3 study of Carcinoma, Hepatocellular that has completed, run by Hoffmann-La Roche. The registered enrollment target is 558 participants, roughly in line with the 592-participant average among 27 other Carcinoma, Hepatocellular trials with a reported enrollment target. The trial reports 20 study locations across 12 states.
The verdict
NCT03434379, a Phase 3 study of Carcinoma, Hepatocellular, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 558 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the efficacy and safety of atezolizumab in combination with bevacizumab compared with sorafenib in participants with locally advanced or metastatic Hepatocellular Carcinoma (HCC) who have received no prior systemic treatment.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Atezolizumab
- DRUG Sorafenib
Study Locations (20)
California
- City of Hope - Duarte
- Uni of California - San Diego; Cancer Center & Dept of Medicine - La Jolla
- Kaiser Permanente Northern California - Novato
- University of California Irvine Medical Center - Orange
- Kaiser Permanente Sacramento Medical Center - Sacramento
- California Pacific Medical Center - San Francisco
- Kaiser Permanente - San Francisco Medical Center - San Francisco
- University of California Los Angeles - Santa Monica
- Kaiser Permanente - Walnut Creek - Walnut Creek
Arizona
- St. Josephs Hospital and Medical Center - Phoenix
Colorado
- Banner MD Anderson Cancer Center - Greeley
District of Columbia
- Georgetown University - Washington D.C.
Florida
- Moffitt Cancer Center - Tampa
Massachusetts
- Massachusetts General Hospital - Boston
Michigan
- Henry Ford Health System - Detroit
Missouri
- Washington University; Wash Uni. Sch. Of Med - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 558 participants |
| Start Date | 2018-03-15 |
| Est. Completion | 2022-11-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03434379
The ClinicalTrials.gov registry entry for NCT03434379 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 558 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 592-participant average among 27 other Carcinoma, Hepatocellular trials with a reported enrollment target. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Carcinoma, Hepatocellular appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.
NCT03434379 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT03434379 about?
NCT03434379 is a clinical study titled "A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma". This study will evaluate the efficacy and safety of atezolizumab in combination with bevacizumab compared with sorafenib in participants with locally advanced or metastatic Hepatocellular Carcinoma (HCC) who have received no prior systemic treatment.
What is the current status of trial NCT03434379?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 558 participants. The study started on 2018-03-15. Estimated completion is 2022-11-17.
What conditions does trial NCT03434379 study?
This clinical trial studies the following conditions: Carcinoma, Hepatocellular.
What interventions are being tested in trial NCT03434379?
The interventions under investigation include: Bevacizumab (DRUG), Atezolizumab (DRUG), Sorafenib (DRUG).
Who is sponsoring clinical trial NCT03434379?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03434379 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Hepatocellular
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
ACTIVE NOT RECRUITING · Phase 3
-
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
ACTIVE NOT RECRUITING · Phase 3
-
Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)
COMPLETED · Phase 3
-
Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma
COMPLETED · Phase 3
-
A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
COMPLETED · Phase 3
-
90Y Transarterial Radioembolization Versus Microwave Ablation in Small Hepatocellular Carcinoma With Hypoalbuminemia
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.